Where does Dyne Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$446.21M-40.6%	-$317.42M-34.5%	-$235.94M-40.4%	-$168.1M-12.6%
Depreciation and amortization	$2.02M+23.7%	$1.64M+1.6%	$1.61M-6.7%	$1.73M+60.0%
Stock-based compensation	$45.85M0.0%	$45.86M+130%	$19.97M+31.6%	$15.18M-13.5%
Net cash from operating activities	-$403.21M-37.9%	-$292.37M-55.4%	-$188.16M-22.5%	-$153.65M-28.5%
Capital expenditures	$1.92M-19.2%	$2.38M+226%	$729K-76.2%	$3.07M-15.2%
Net cash from investing activities	-$29.73M+86.2%	-$215.25M-358%	$83.31M-4.5%	$87.2M+163%
Proceeds from issuance of debt	——	——	$0—	——
Net cash from financing activities	$890.31M+9.9%	$809.9M+1,391%	$54.32M+45.3%	$37.39M-76.3%
Net increase (decrease) in cash	$458.35M—	——	-$50.53M—	——
Free cash flow	-$405.13M-37.4%	-$294.75M-56.0%	-$188.89M-20.5%	-$156.71M-27.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dyne Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.